전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved57 programs
AntibodyCurated CoreRochePhase 2

Avastin (Avastin)

Neovascular Age-Related Macular Degeneration · Extranodal NK/T-cell Lymphoma, Nasal Typ

#ExtranodalNKT-cellLymphomaNasalT#Antibody#Phase2#BioJungboMoa-pick#Popular+3
Trials 1444Status Active
ADCStandard DatabasestaleSeagenVedotin: A Retrospective Co…Phase 2

BV (Induction with Brentuximab vedotin, Induction with Brentuximab vedotin (BV))

Hodgkin Lymphoma, Adult · Hodgkin Lymphoma, Adult

#HodgkinLymphomaAdult#ADC#Phase2#Popular#antibody-drug-conjugate+5
Trials 119Status Recruiting
CGTStandard DatabasestaleShanghai Ming Ju Biotechnology …Phase 2

CD19-targeted Chimeric Antigen Receptor (CAR, CD19-targeted Chimeric Antigen Receptor, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 64Status Active
CGTStandard DatabasestaleSanofiPhase 2

gemcitabin (gemcitabin)

Extranodal NK/T-cell Lymphoma, Nasal Type · Extranodal NK/T-cell Lymphoma, Nasal Typ

#ExtranodalNKT-cellLymphomaNasalT#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 61Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells)

Lymphoma, B-Cell; Lymphoma, Non-hodgkins · CD19

#CD19#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 55Status Active
ADCStandard DatabasestaleSeagenvedotin-containing regimen …Phase 2

Adcetris (Brentuximab vedotin, Brentuximab vedotin (Adcetris))

Anaplastic Large Cell Lymphoma, ALK-Positive · Anaplastic Large Cell Lymphoma, ALK-Posi

#AnaplasticLargeCellLymphomaALK-P#ADC#Phase2#Popular#antibody-drug-conjugate+5
Trials 51Status Recruiting
CGTStandard DatabasestaleJuno Therapeutics, a Subsidiary…Phase 2

lisocabtagene maraleucel (JCAR017, JCAR017 (lisocabtagene maraleucel))

Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Small Lymphocytic · Leukemia, Lymphocytic, Chronic, B-Cell

#LeukemiaLymphocyticChronicB-Cell#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 34Status Recruiting
CGTLimited DatastaleNanjing IASO Biotechnology Co.,…Preclinical

chimeric antigen receptor gene modified T cells (chimeric antigen receptor gene modified T cells)

Lymphoma, B-Cell · CD30

#CD30#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 30Status Recruiting
ADCStandard DatabasestaleDaiichi SankyoPhase 2

TDxD (Fam-Trastuzumab Deruxtecan-Nxki, Fam-Trastuzumab Deruxtecan-Nxki (TDxD))

Gastric Cancer; Gastrointestinal Cancer · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#ADC#Phase2#antibody-drug-conjugate#GastricCancer+2
Trials 27Status Recruiting
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Consolidation with Brentuximab Vedotin)

Hodgkin Lymphoma, Adult · Hodgkin Lymphoma, Adult

#HodgkinLymphomaAdult#ADC#Phase2#antibody-drug-conjugate#HodgkinLymphoma+2
Trials 25Status Recruiting
CGTStandard DatabasestaleCelgenePhase 3

JCAR017 (JCAR017)

Lymphoma, Non-Hodgkin · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#CGT#Phase3#cell-gene-therapy#CAR-T+4
Trials 20Status Active
ADCStandard DatabasestaleMerck Sharp & Dohme LLCPhase 2

Zilovertamab vedotin (Zilovertamab vedotin)

Lymphoma, Large B-Cell, Diffuse · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#Lymphoma+3
Trials 10Status Active
AntibodyLimited DatastaleInnoventPhase 2

Sintilimab+Pegaspargase (Sintilimab+Pegaspargase)

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · Natural Killer/T-Cell Lymphoma, Nasal an

#NaturalKillerT-CellLymphomaNasal#Antibody#Phase2#monoclonal-antibody#NaturalKiller+3
Trials 8Status Recruiting
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy (Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy)

Lymphoma, B-Cell · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 5Status Discontinued
ADCStandard DatabasestaleSeagen Inc.Phase 2

denintuzumab mafodotin (denintuzumab mafodotin)

Lymphoma, B-cell; Lymphoma, Large B-Cell, Diffuse · Lymphoma, B-cell

#LymphomaB-cell#ADC#Phase2#antibody-drug-conjugate#Lymphoma+2
Trials 4Status Discontinued
CGTLimited DatastaleMedical College of WisconsinPhase 1

1.0 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

2.5 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

2.5 x10^6 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

7.5 x10^5 CAR-20/19-T cells/kg (CAR-20/19-T cells, CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg))

Lymphoma, Non-Hodgkin; Lymphoma, B-Cell · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Active
CGTLimited DatastaleKecellitics Biotech Company LtdPhase 2

CD19 and CD22 targeted CAR-T cells (CD19 and CD22 targeted CAR-T cells)

Lymphoma, B-Cell · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 3Status Active

1 / 3 pages

← PreviousNext →